E

Eisai Asia

51 employees

Eisai is a pharmaceutical company that researches and delivers medicines for patients.

Investor insights

Sectors invested in

Biotechnology8
Health Care7
Medical5
Life Science5
Therapeutics3
Information and Communications Technology (ICT)2
Information Technology2
Health Diagnostics2
Pharmaceutical2
Artificial Intelligence2
Machine Learning2
oligonucleotide therapeutics and saRNA drug1
Life Insurance1
Financial Services1
Insurance1
InsurTech1
Biopharma1
Software1
Enterprise Software1
Bioinformatics1

Funding rounds participated in

$12M sweet spot round size

Most of their 12 investments are in rounds between $3M and $25M

Basic info

Industry

pharmaceutical manufacturing

Sectors

Biotechnology
Health Care
Pharmaceutical

Date founded

1941

Investments made

C

Casma Therapeutics raised $46M on November 15, 2022

Investors: Eventide Management Partners, Schroders Capital, Astellas Venture Capital L.L.C., The Column Group, Mirae Asset MAPS Global Investments Co., Ltd, Third Rock Ventures and Eisai Asia

ライフネット生命保険(株) raised $2.2M on August 9, 2022

Investors: Eisai Asia

中美瑞康医药科技(南通)有限公司 raised $30M on January 27, 2022

Investors: 襄禾商务咨询(北京)有限公司 and Eisai Asia

N

Neuroglee Therapeutics raised $10M on September 9, 2021

Investors: Openspace Ventures, EDBI Pte Ltd and Eisai Asia

A

Allm Inc. raised $50M on April 5, 2021

Investors: SBI Investment, Vector Holdings, Sompo Holdings (Asia), Cyberdyne and Eisai Asia

N

Neuroglee Therapeutics raised $2.3M on December 3, 2020

Investors: Eisai Asia

U

Unlearn.AI raised $3M on November 5, 2020

Investors: Alumni Ventures Group and Eisai Asia

D

Darmiyan raised $6.4M on April 10, 2020

Investors: Y Combinator, - and Eisai Asia

N

Numab Therapeutics AG raised $22M on December 12, 2019

Investors: Eisai Asia

A

Allm Inc. raised undisclosed on May 9, 2019

Investors: Eisai Asia

FAQ